Medtronic PLC and Aetna Inc. have signed an outcomes-based agreement regarding reimbursement of the medtech giant's self-adjusting insulin pump systems. If patients fall outside of the agreed-upon A1C range, Medtronic will pay Aetna a rebate. (Also see "Medtronic Enters New Outcomes-Based Insulin Pump Deal With Aetna" - Medtech Insight, 27 June, 2017.) Medtronic has a similar deal with UnitedHealth Group Co. and plans to work with other payers as well.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?